Advertisement
Screener

CYPHERPUNK TECHNOLOGIES INC. (CYPH) Net Income

CYPHERPUNK TECHNOLOGIES INC. Net Income

CYPHERPUNK TECHNOLOGIES INC. (CYPH) reported Net Income of $39.39 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.

Financial Statements › Income Statement › Net Income

us-gaap:NetIncomeLoss · last filed 2026-08-12

  • CYPHERPUNK TECHNOLOGIES INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was $39.39M.
  • CYPHERPUNK TECHNOLOGIES INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was -$77.17M.
  • CYPHERPUNK TECHNOLOGIES INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was $40.38M.
  • CYPHERPUNK TECHNOLOGIES INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was -$3.30M.
  • CYPHERPUNK TECHNOLOGIES INC. net income (loss) attributable to parent for fiscal 2022 was -$54.60M.
  • CYPHERPUNK TECHNOLOGIES INC. net income (loss) attributable to parent for fiscal 2021 was -$40.59M.
  • CYPHERPUNK TECHNOLOGIES INC. net income (loss) attributable to parent for fiscal 2020 was -$27.51M.
  • CYPHERPUNK TECHNOLOGIES INC. net income (loss) attributable to parent for fiscal 2019 was -$32.90M.
Period endNet Income (Loss) Attributable to Parent 3 monthNet Income (Loss) Attributable to Parent 6 monthNet Income (Loss) Attributable to Parent 9 monthNet Income (Loss) Attributable to Parent 12 monthNet Income (Loss) Attributable to Parent 12 month as first filed
2026-06-30$39.39M
10-Q · filed 2026-08-12
-$37.78M
10-Q · filed 2026-08-12
$2.60M
derived: sum of 3 quarters · filed 2026-08-12
-$699.00K
derived: sum of 4 quarters · filed 2026-08-12
2026-03-31-$77.17M
10-Q · filed 2026-05-14
-$36.78M
derived: sum of 2 quarters · filed 2026-05-14
-$40.09M
derived: sum of 3 quarters · filed 2026-05-14
-$56.73M
derived: sum of 4 quarters · filed 2026-08-12
2025-12-31$40.38M
derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29
$37.08M
derived: sum of 2 quarters · filed 2026-04-29
$20.43M
derived: sum of 3 quarters · filed 2026-08-12
$5.00M
DEF 14A · filed 2026-04-29
$4.82M
10-K · filed 2026-03-16
2025-09-30-$3.30M
10-Q · filed 2025-11-12
-$19.95M
derived: sum of 2 quarters · filed 2026-08-12
-$35.38M
10-Q · filed 2025-11-12
-$51.26M
derived: sum of 4 quarters · filed 2026-08-12
2025-06-30-$16.64M
10-Q · filed 2026-08-12
-$32.08M
10-Q · filed 2026-08-12
-$47.95M
derived: sum of 3 quarters · filed 2026-08-12
-$66.13M
derived: sum of 4 quarters · filed 2026-08-12
2025-03-31-$15.44M
10-Q · filed 2026-05-14
-$31.31M
derived: sum of 2 quarters · filed 2026-05-14
-$49.49M
derived: sum of 3 quarters · filed 2026-05-14
-$69.61M
derived: sum of 4 quarters · filed 2026-05-14
2024-12-31-$15.88M
derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29
-$34.05M
derived: sum of 2 quarters · filed 2026-04-29
-$54.18M
derived: sum of 3 quarters · filed 2026-04-29
-$68.00M
DEF 14A · filed 2026-04-29
-$67.56M
10-K · filed 2025-03-26
2024-09-30-$18.18M
10-Q · filed 2025-11-12
-$38.30M
derived: sum of 2 quarters · filed 2025-11-12
-$52.12M
10-Q · filed 2025-11-12
-$64.17M
derived: sum of 4 quarters · filed 2026-04-29
2024-06-30-$20.13M
10-Q · filed 2025-08-14
-$33.95M
10-Q · filed 2025-08-14
-$46.00M
derived: sum of 3 quarters · filed 2026-04-29
-$59.70M
derived: sum of 4 quarters · filed 2026-04-29
2024-03-31-$13.82M
10-Q · filed 2025-05-13
-$25.87M
derived: sum of 2 quarters · filed 2026-04-29
-$39.57M
derived: sum of 3 quarters · filed 2026-04-29
-$52.96M
derived: sum of 4 quarters · filed 2026-04-29
2023-12-31-$12.05M
derived: DEF 14A 12 month − 10-Q 9 month · filed 2026-04-29
-$25.75M
derived: sum of 2 quarters · filed 2026-04-29
-$39.14M
derived: sum of 3 quarters · filed 2026-04-29
-$81.00M
DEF 14A · filed 2026-04-29
-$81.41M
10-K · filed 2024-03-18
2023-09-30-$13.70M
10-Q · filed 2024-11-13
-$27.09M
derived: sum of 2 quarters · filed 2024-11-13
-$68.95M
10-Q · filed 2024-11-13
-$81.05M
derived: sum of 4 quarters · filed 2024-11-13
2023-06-30-$13.39M
10-Q · filed 2024-08-12
-$55.25M
10-Q · filed 2024-08-12
-$67.36M
derived: sum of 3 quarters · filed 2024-08-12
-$82.45M
derived: sum of 4 quarters · filed 2024-08-12
2023-03-31-$41.86M
10-Q · filed 2024-05-13
-$53.97M
derived: sum of 2 quarters · filed 2024-05-13
-$69.06M
derived: sum of 3 quarters · filed 2024-05-13
-$86.08M
derived: sum of 4 quarters · filed 2024-05-13
2022-12-31-$12.10M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-18
-$27.20M
derived: sum of 2 quarters · filed 2024-03-18
-$44.22M
derived: sum of 3 quarters · filed 2024-03-18
-$54.60M
10-K · filed 2024-03-18
2022-09-30-$15.09M
10-Q · filed 2023-11-13
-$32.12M
derived: sum of 2 quarters · filed 2023-11-13
-$42.49M
10-Q · filed 2023-11-13
-$53.28M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$17.02M
10-Q · filed 2023-08-14
-$27.40M
10-Q · filed 2023-08-14
-$38.19M
derived: sum of 3 quarters · filed 2023-08-14
-$49.33M
derived: sum of 4 quarters · filed 2023-08-14
2022-03-31-$10.38M
10-Q · filed 2023-05-15
-$21.16M
derived: sum of 2 quarters · filed 2023-05-15
-$32.30M
derived: sum of 3 quarters · filed 2023-05-15
-$41.83M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31-$10.79M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-24
-$21.93M
derived: sum of 2 quarters · filed 2023-03-24
-$31.45M
derived: sum of 3 quarters · filed 2023-03-24
-$40.59M
10-K · filed 2023-03-24
2021-09-30-$11.14M
10-Q · filed 2022-11-14
-$20.66M
derived: sum of 2 quarters · filed 2022-11-14
-$29.80M
10-Q · filed 2022-11-14
-$36.51M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$9.53M
10-Q · filed 2022-08-12
-$18.66M
10-Q · filed 2022-08-12
-$25.37M
derived: sum of 3 quarters · filed 2022-08-12
-$32.43M
derived: sum of 4 quarters · filed 2022-08-12
2021-03-31-$9.13M
10-Q · filed 2022-05-13
-$15.84M
derived: sum of 2 quarters · filed 2022-05-13
-$22.90M
derived: sum of 3 quarters · filed 2022-05-13
-$29.42M
derived: sum of 4 quarters · filed 2022-05-13
2020-12-31-$6.71M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11
-$13.77M
derived: sum of 2 quarters · filed 2022-03-11
-$20.28M
derived: sum of 3 quarters · filed 2022-03-11
-$27.51M
10-K · filed 2022-03-11
2020-09-30-$7.06M
10-Q · filed 2021-11-12
-$13.57M
derived: sum of 2 quarters · filed 2021-11-12
-$20.80M
10-Q · filed 2021-11-12
-$28.80M
derived: sum of 4 quarters · filed 2021-11-12
2020-06-30-$6.52M
10-Q · filed 2021-08-13
-$13.75M
10-Q · filed 2021-08-13
-$21.74M
derived: sum of 3 quarters · filed 2021-08-13
-$29.68M
derived: sum of 4 quarters · filed 2021-08-13
2020-03-31-$7.23M
10-Q · filed 2021-05-14
-$15.23M
derived: sum of 2 quarters · filed 2021-05-14
-$23.16M
derived: sum of 3 quarters · filed 2021-05-14
-$31.53M
derived: sum of 4 quarters · filed 2021-05-14
2019-12-31-$8.00M
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-12
-$15.93M
derived: sum of 2 quarters · filed 2021-03-12
-$24.30M
derived: sum of 3 quarters · filed 2021-03-12
-$32.90M
10-K · filed 2021-03-12
2019-09-30-$7.93M
10-Q · filed 2020-11-12
-$16.30M
derived: sum of 2 quarters · filed 2020-11-12
-$24.90M
10-Q · filed 2020-11-12
-$23.42M
derived: sum of 4 quarters · filed 2020-11-12
2019-06-30-$8.37M
10-Q · filed 2020-08-13
-$16.97M
10-Q · filed 2020-08-13
-$15.49M
derived: sum of 3 quarters · filed 2020-08-13
-$22.12M
derived: sum of 4 quarters · filed 2020-08-13
2019-03-31-$8.60M
10-Q · filed 2020-05-14
-$7.12M
derived: sum of 2 quarters · filed 2020-05-14
-$13.76M
derived: sum of 3 quarters · filed 2020-05-14
-$21.12M
derived: sum of 4 quarters · filed 2020-05-14
2018-12-31$1.48M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16
-$5.15M
derived: sum of 2 quarters · filed 2020-03-16
-$12.52M
derived: sum of 3 quarters · filed 2020-03-16
-$23.14M
10-K · filed 2020-03-16
2018-09-30-$6.63M
10-Q · filed 2019-11-14
-$14.00M
derived: sum of 2 quarters · filed 2019-11-14
-$24.62M
10-Q · filed 2019-11-14
-$31.21M
derived: sum of 4 quarters · filed 2019-11-14
2018-06-30-$7.36M
10-Q · filed 2019-08-09
-$17.99M
10-Q · filed 2019-08-09
-$24.58M
derived: sum of 3 quarters · filed 2019-08-09
-$31.39M
derived: sum of 4 quarters · filed 2019-08-09
2018-03-31-$10.62M
10-Q · filed 2019-05-15
-$17.21M
derived: sum of 2 quarters · filed 2019-05-15
-$24.03M
derived: sum of 3 quarters · filed 2019-05-15
-$30.93M
derived: sum of 4 quarters · filed 2019-05-15
2017-12-31-$6.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2019-04-01
-$13.41M
derived: sum of 2 quarters · filed 2019-04-01
-$20.31M
derived: sum of 3 quarters · filed 2019-04-01
-$29.73M
10-K · filed 2019-04-01
2017-09-30-$6.82M
10-Q · filed 2018-11-09
-$13.72M
derived: sum of 2 quarters · filed 2018-11-09
-$23.13M
10-Q · filed 2018-11-09
-$28.86M
derived: sum of 4 quarters · filed 2018-11-09
2017-06-30-$6.91M
10-Q · filed 2018-08-08
-$16.32M
10-Q · filed 2018-08-08
-$22.05M
derived: sum of 3 quarters · filed 2018-08-08
-$29.33M
derived: sum of 4 quarters · filed 2018-08-08
2017-03-31-$9.41M
10-Q/A · filed 2018-08-08
-$15.14M
derived: sum of 2 quarters · filed 2018-08-08
-$22.42M
derived: sum of 3 quarters · filed 2018-08-08
-$29.90M
derived: sum of 4 quarters · filed 2018-08-08
2016-12-31-$5.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23
-$13.01M
derived: sum of 2 quarters · filed 2018-02-23
-$20.48M
derived: sum of 3 quarters · filed 2018-02-23
-$25.63M
10-K · filed 2018-02-23
2016-09-30-$7.28M
10-Q · filed 2017-11-13
-$14.75M
derived: sum of 2 quarters · filed 2017-11-13
-$19.90M
10-Q · filed 2017-11-13
2016-06-30-$7.48M
10-Q · filed 2017-08-11
-$12.62M
10-Q · filed 2017-08-11
2016-03-31-$5.15M
10-Q · filed 2017-05-12

Similar stocks

Stock NameCountryMarket CapPE Ratio
Quoin Pharmaceuticals Ltd. (QNRX)$0.443B-17.85
PROTHENA CORP PUBLIC LTD CO (PRTA)Ireland$0.428B-11.53
DiaMedica Therapeutics Inc. (DMAC)United States$0.423B-10.11
MapLight Therapeutics, Inc. (MPLT)United States$0.459B-7.10
Atea Pharmaceuticals, Inc. (AVIR)United States$0.414B-2.26
ARS Pharmaceuticals, Inc. (SPRY)United States$0.414B-3.70
RELMADA THERAPEUTICS, INC. (RLMD)United States$0.406B-11.92
Opus Genetics, Inc. (IRD)United States$0.406B-3.16
Arcturus Therapeutics Holdings Inc. (ARCT)$0.402B-2.05
GALECTIN THERAPEUTICS INC (GALT)United States$0.399B-11.06